COSCIENS Provides Strategic Update
MWN-AI** Summary
COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) has announced a strategic update indicating its decision to stop funding its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH. This drastic step follows the realization that these subsidiaries, which have historically operated at a loss, will likely enter a structured insolvency process soon. The subsidiaries were primarily engaged in developing MACRILEN® (macimorelin), an FDA and EMA-approved oral test for diagnosing growth hormone deficiency in adults. Despite its availability in several markets, the lack of profitable operations was exacerbated by disappointing outcomes from MACRILEN's Phase 3 DETECT trial and setbacks concerning gaining pediatric approval in the U.S.
As part of its ongoing strategic review, COSCIENS has been exploring various options, including selling its products or the subsidiaries themselves, in addition to seeking new licensing and partnership opportunities. The company recently entered into a distribution agreement with Wuzhou Drug International Trading Limited but concluded that terminating funding for the subsidiaries was crucial for future profitability.
Interim CEO Peter Puccetti emphasized that this decision, though difficult, sets the stage for COSCIENS to refocus on enhancing profitability in its active ingredients business. The company aims to utilize its proprietary technologies for developing natural, plant-based active ingredients, which are currently featured in leading skincare products globally. This shift is positioned as a transformative opportunity for COSCIENS to evaluate new prospects and streamline expenses effectively.
For investors and stakeholders, forward-looking statements in the announcement highlight the inherent uncertainties and risks but reflect COSCIENS' intention to adapt and evolve strategically in response to its current challenges.
MWN-AI** Analysis
COSCIENS Biopharma Inc. (TSX: CSCI) has recently made a pivotal move by ceasing funding for its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH, initiating a structured insolvency process. This decision, although difficult, signals a strategic pivot aimed at stabilizing the company's financial outlook.
The announcement stems from the disappointing results of Macrilen’s Phase 3 DETECT trial and subsequent challenges with the FDA regarding pediatric approval in the U.S. Historically, the biopharmaceutical segment, which includes Macrilen, has been a financial burden, operating at a loss. By surrendering its rights to Macrilen and ceasing further financing, COSCIENS aims to alleviate ongoing operational expenses, thereby redirecting focus towards its more promising natural, plant-based active ingredients business.
Investors should consider these developments as indicative of COSCIENS’ commitment to streamlining and achieving profitability. The decision could initially create volatility in the company’s stock price, as market participants react to the implications of the insolvency process. However, it also paves the way for a leaner operational structure that prioritizes their manufacturing capabilities in the skincare ingredients sector.
Moreover, the recently announced distribution agreement with Wuzhou Drug International Trading Limited indicates that while the biopharmaceutical strategy is being abandoned, COSCIENS is still pursuing growth avenues. For investors, this could represent a potential opportunity. The shift towards a focus on active ingredients positions the company in a growing market where demand for natural and effective solutions is increasing.
In summary, COSCIENS’ recent strategic update highlights a necessary realignment away from underperforming assets towards potentially more lucrative ventures. Investors should keep an eye on the company’s moves in the plant-based ingredient space and be prepared for some short-term fluctuations as the restructuring unfolds, but view this as an opportunity for long-term value creation.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”) today announced that the Company has made a strategic decision to cease funding its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH (the “German Subsidiaries”). As a result, the Company expects the German Subsidiaries to commence a structured insolvency process in the near future.
The Company has historically pursued the development of its pharmaceutical therapeutic assets, including its main pharmaceutical asset, Macrilen® (macimorelin), via its German Subsidiaries (collectively, the “Biopharmaceutical Business”). Macrilen is an FDA and EMA approved oral test indicated for the diagnosis of adults with growth hormone deficiency and is commercially available in a number of countries, but the Biopharmaceutical Business has historically operated at a loss. The long-term viability of the business has always been largely dependent on the Company’s ability to expand the market for Macrilen, either by obtaining FDA approval for a pediatric indication in the U.S., or otherwise. In light of the disappointing results of Macrilen’s Phase 3 DETECT trial and subsequent Type C meeting with the FDA (which represented a significant setback to the Company’s hopes for a full pediatric approval in the U.S.), the Company has been undertaking a strategic review of its options, including by exploring the viability of (i) alternative options for expansion into the U.S. market, (ii) a possible sale of the product and/or of the German Subsidiaries, and (iii) additional licensing and partnership opportunities. Despite the recently announced distribution agreement with Wuzhou Drug International Trading Limited, it was determined that the best path forward for the Company and its shareholders was to cease providing any further financing to the German Subsidiaries.
As a result of the expected insolvency process, the Company anticipates surrendering its rights to Macrilen and significantly reducing its ongoing operating expenses. Peter Puccetti, Interim CEO and Chairman of the Board, commented, “The Board did not make this decision lightly, but we firmly believe it marks a significant and positive step towards the Company’s goal of achieving profitability. Going forward, the Company will continue to focus on maximizing the profitability of its active ingredients business and to evaluate other opportunities.”
About COSCIENS Biopharma Inc.
COSCIENS is a life science company focused on the development of natural, plant-based active ingredients, leveraging the Company’s proprietary manufacturing and extraction technologies to develop Avenanthramides and Beta Glucan active ingredients currently used in leading skincare brands worldwide.
Forward-Looking Statements
Certain statements in this news release, referred to herein as "forward-looking statements", constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and "forward-looking information" under the provisions of Canadian securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this news release, words such as "anticipate", "assume", "believe", "could", "expect", "forecast", "future", "goal", "guidance", "intend", "likely", "may", "would" or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words. Forward-looking statements in this news release include, but are not limited to, statements relating to the expectations regarding an insolvency process in respect of the German Subsidiaries, including the timing and implications thereof.
These statements are based on current expectations and assumptions, including factors or assumptions factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from those expressed or implied by such forward-looking statements, including but not limited to the factors described in “Risks Relating to Us and Our Business” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2024. Given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of their dates. We disclaim any obligation to update any such risks or uncertainties or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.
Issuer Contact:
Peter H. Puccetti
Interim CEO and Chairman of the Board
pp@cosciensbio.com
Giuliano La Fratta
Chief Financial Officer
glafratta@cosciensbio.com
Investor Contact:
IR@cosciensbio.com
FAQ**
What are the primary reasons behind COSCIENS Biopharma Inc. CSCIF's decision to cease funding its German subsidiaries, and how will this impact the company's overall strategy moving forward?
In light of the setbacks with Macrilen, what alternative options is COSCIENS Biopharma Inc. CSCIF exploring to expand into the U.S. market, beyond the distribution agreement with Wuzhou Drug International Trading Limited?
How does COSCIENS Biopharma Inc. CSCIF plan to mitigate the financial losses it has incurred from its biopharmaceutical business as it shifts focus to maximizing the profitability of its active ingredients business?
What specific opportunities for licensing and partnership is COSCIENS Biopharma Inc. CSCIF currently evaluating, and how might these efforts offset the impact of the expected insolvency of its German subsidiaries?
**MWN-AI FAQ is based on asking OpenAI questions about COSCIENS Biopharma Inc. (OTC: CSCIF).
NASDAQ: CSCIF
CSCIF Trading
-5.66% G/L:
$1.50 Last:
236 Volume:
$1.59 Open:
